Physician profile
Suprabha Bhat
NPI 1972501047
$4,133.60
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $722 · 2021: $660 · 2022: $1,045 · 2023: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $593.15 | 2019-2022 | |
| Sk Life Science, INC. | $445.52 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $382.33 | 2019-2023 | |
| Genentech USA, INC. | $253.01 | 2019-2022 | |
| Ucb, INC. | $221.17 | 2019-2023 | Briviact |
| Sumitomo Pharma America, INC. | $200.41 | 2023 | Aptiom |
| Abbvie INC. | $195.82 | 2020-2023 | Botox, Duopa |
| Neurocrine Biosciences, INC. | $172.40 | 2022-2023 | Ongentys, Ingrezza |
| Biogen, INC. | $148.17 | 2019-2023 | Vumerity, Tysabri |
| Emd Serono, INC. | $136.99 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $134.27 | 2019-2023 | Nuplazid |
| Eisai INC. | $132.30 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $119.22 | 2019-2023 | Oxtellar Xr |
| Abbott Laboratories | $118.34 | 2019 | |
| Lilly USA, LLC | $117.44 | 2022-2023 | Emgality |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $116.36 | 2021-2022 | |
| Genentech, INC. | $95.90 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $92.32 | 2019 | |
| Mallinckrodt Hospital Products INC. | $78.32 | 2021-2022 | |
| Medtronic USA, INC. | $68.63 | 2019 | |
| Amneal Pharmaceuticals LLC | $45.39 | 2021-2023 | Rytary |
| Kyowa Kirin, INC. | $44.75 | 2020-2022 | |
| Ge Healthcare | $38.28 | 2019-2022 | |
| Livanova USA, INC. | $35.16 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Grt US Holding, INC. | $31.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.21 | 2020 | |
| Neurelis, INC. | $17.22 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.20 | 2019 | |
| Allergan, INC. | $15.19 | 2020 | |
| Adamas Pharmaceuticals, INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suprabha Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.